Skip to main content
OpenTrials
Completed

NCT Number: NCT04176224

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral Sclerosis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Japanese Patients With ALS

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigational site

Tokyo, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The key criteria are listed below.

  • Patients aged between 20 and 75 years at the time of informed consent
  • Japanese patients
  • Among patients with ALS, those "Clinically definite ALS," "Clinically probable ALS" or "Clinically probable-laboratory-supported ALS" according to El Escorial Revised Airlie House criteria
  • Patients who can consent to contraception
  • Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion criteria

The key criteria are listed below.

  • Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy
  • Patients undergoing treatment for malignancy
  • Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator
  • Body mass index (BMI) of <18.0 or >30.0, or a body weight of <50 kg
  • Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason

Treatment and study plan

MT-1186

Drug

Suspension

Other names: Edaravone

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  2. Maximum Plasma Concentration (Cmax) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  3. Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  4. Terminal Elimination Half-life (t1/2) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  5. Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  6. Mean Residence Time (MRT) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  7. Apparent Total Clearance (CL/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  8. Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  9. Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 at 24 hours after administration.

  10. Cumulative Amount of Drug Excreted in Urine From Time Zero up to 24 Hours (Ae0-24) of Unchanged Edaravone

    Time frame: Urine samples are collected: 0 to 24 hours after oral administration

  11. Cumulative Percentage of Drug Excreted in Urine From Time Zero up to 24 Hours (Ae0-24) of Unchanged Edaravone

    Time frame: Urine samples are collected: 0 to 24 hours after oral administration

  12. Renal Clearance (CLr) of Unchanged Edaravone

    Time frame: Urine samples are collected: 0 to 24 hours after oral administration

Secondary outcomes

  1. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: Day 1 to 8

Sponsors and collaborators

Lead sponsor

Shionogi

Industry

Registry information

Official study title

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Nov 25, 2019
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.